Conference Report

Update on Metabolic Complications and Adverse Effects in HIV

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Update on Metabolic Complications and Adverse Effects in HIV

Faculty:

Judith S. Currier, MD, MSc
William G. Powderly, MD

CME CREDIT INFORMATION

Release Date: 09/27/07

Expiration Date: 09/26/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize recent data regarding adverse effects and metabolic perturbations associated with antiretroviral agents
Describe insights into the pathogenesis of adverse effects and metabolic complications in HIV-infected patients
Discuss the results of studies of prevention and management strategies for adverse effects and metabolic complications in HIV-infected patients

Topics covered include:

Introduction
Hypersensitivity Reaction Rates Upon Switching to Nevirapine
Metabolic Complications in a US Pediatric Cohort
Role of PIs vs Thymidine Analogues in Metabolic Abnormalities
The Growth Hormone-Releasing Hormone tesamorelin for Lipohypertrophy
Short-term Antiretroviral Therapy Reverses Endothelial Dysfunction
Coronary Calcification as a Marker of Cardiovascular Risk
Is Diabetes Equivalent to Previous CHD as a Risk Factor for CHD in HIV-Infected patients?
Bone Disease Progression With Antiretroviral Therapy
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.